CF
TGTX icon

Cantor Fitzgerald’s TG Therapeutics TGTX Stock Holding History

Cantor Fitzgerald’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-32,000
Closed -$1.16M – 366
2025
Q3 		$1.16M Buy
32,000
+1,000
+3% +$32.9K 0.01% 200
2025
Q2 		$1.12M Buy
+31,000
New +$1.15M 0.02% 146

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Cantor Fitzgerald's TGTX Position: Q4 2025 in Review

Cantor Fitzgerald sold out of TG Therapeutics (TGTX) in Q4 2025, closing a stake of 32,000 shares — an estimated $1.16M sold.

Cantor Fitzgerald first reported a position in TGTX in Q2 2025 and held it in 2 quarters. The position peaked at $1.16M in Q3 2025. 351 funds tracked by Wall St. Rank hold TGTX as of Q4 2025.

  • Cantor Fitzgerald reported no remaining TG Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Cantor Fitzgerald sold 32,000 TG Therapeutics shares in Q4 2025, an estimated $1.16M.
  • Cantor Fitzgerald first reported a position in TG Therapeutics in Q2 2025 and held it in 2 quarters.
  • Cantor Fitzgerald's TG Therapeutics position peaked at $1.16M in Q3 2025.
  • 351 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2025.

Based on Cantor Fitzgerald's 13F filing for Q4 2025, filed 17 Feb 2026.